Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson's financial results are generally ... a new law in the U.S. that gives Medicare the power to negotiate drug prices. The first round of negotiations will target three of the ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019, but could only be prescribed ...